Upgrade to SI Premium - Free Trial

Avalyn Pharma (AVLN)

28.17 -0.36 (1.26%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (9/2/26)

Latest Headlines

Form 10-Q Avalyn Pharma Inc. For: Mar 31 June 3, 2026 8:01 AM - SEC Filing Form 8-K Avalyn Pharma Inc. For: Jun 03 June 3, 2026 7:25 AM - SEC Filing Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights June 3, 2026 7:00 AM - StreetInsider Avalyn to Participate in the Jefferies Global Healthcare Conference May 27, 2026 8:00 AM - Globe NewsWire Evercore ISI Starts Avalyn Pharma (AVLN) at Outperform May 26, 2026 7:41 AM - StreetInsider Morgan Stanley Starts Avalyn Pharma (AVLN) at Overweight May 26, 2026 12:54 AM - StreetInsider Jefferies Starts Avalyn Pharma (AVLN) at Buy May 25, 2026 10:31 AM - StreetInsider Guggenheim Starts Avalyn Pharma (AVLN) at Buy May 25, 2026 10:13 AM - StreetInsider Avalyn to present 4-year data on inhaled pirfenidone at EULAR 2026 May 21, 2026 8:03 AM - StreetInsider Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026 May 21, 2026 8:00 AM - StreetInsider Form SCHEDULE 13D Avalyn Pharma Inc. Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC May 8, 2026 6:52 PM - SEC Filing Form SCHEDULE 13D Avalyn Pharma Inc. Filed by: SR ONE CAPITAL MANAGEMENT, LLC May 8, 2026 4:42 PM - SEC Filing Form SCHEDULE 13G Avalyn Pharma Inc. Filed by: PERCEPTIVE ADVISORS LLC May 7, 2026 4:20 PM - SEC Filing Form 4 Avalyn Pharma Inc. For: May 01 Filed by: Novo Holdings A/S May 5, 2026 4:15 PM - SEC Filing Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference May 5, 2026 4:01 PM - StreetInsider Form SCHEDULE 13G Avalyn Pharma Inc. Filed by: FMR LLC May 5, 2026 10:07 AM - SEC Filing Form 4 Avalyn Pharma Inc. For: May 01 Filed by: FMR LLC May 5, 2026 8:38 AM - SEC Filing Form 4 Avalyn Pharma Inc. For: Apr 29 Filed by: Golden Adam H. May 4, 2026 6:06 AM - SEC Filing Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB May 3, 2026 8:00 PM - BizWire Form 4 Avalyn Pharma Inc. For: May 01 Filed by: Carroll Jill May 1, 2026 6:51 PM - SEC Filing Form 4 Avalyn Pharma Inc. For: May 01 Filed by: George Simeon May 1, 2026 6:46 PM - SEC Filing Form 4 Avalyn Pharma Inc. For: Apr 29 Filed by: Congleton Jon May 1, 2026 6:33 PM - SEC Filing Form 4 Avalyn Pharma Inc. For: Apr 29 Filed by: Turner Heather D May 1, 2026 6:30 PM - SEC Filing Form 4 Avalyn Pharma Inc. For: Apr 29 Filed by: Rhodes Melissa May 1, 2026 6:28 PM - SEC Filing Form 4 Avalyn Pharma Inc. For: Apr 29 Filed by: Carlson Douglas R May 1, 2026 6:28 PM - SEC Filing Form 4 Avalyn Pharma Inc. For: Apr 29 Filed by: Haviland Kate May 1, 2026 6:27 PM - SEC Filing Form 4 Avalyn Pharma Inc. For: May 01 Filed by: Wellington Biomedical Innovation Master Investors (Cayman) II L.P. May 1, 2026 6:27 PM - SEC Filing Form 4 Avalyn Pharma Inc. For: Apr 29 Filed by: Lavelle Erin May 1, 2026 6:27 PM - SEC Filing Form 4 Avalyn Pharma Inc. For: Apr 29 Filed by: Lazarus Howard May 1, 2026 6:27 PM - SEC Filing Form 4 Avalyn Pharma Inc. For: Apr 29 Filed by: Baranowski Lyn May 1, 2026 6:26 PM - SEC Filing Avalyn Pharma completes $345 million IPO on nasdaq May 1, 2026 4:01 PM - StreetInsider Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares May 1, 2026 4:01 PM - StreetInsider Form 3 Avalyn Pharma Inc. For: Apr 29 Filed by: Wellington Biomedical Innovation Master Investors (Cayman) II L.P. April 29, 2026 9:58 PM - SEC Filing Avalyn Pharma prices upsized IPO at $18 per share for $300 million April 29, 2026 9:01 PM - StreetInsider Avalyn prices upsized IPO at $18 per share, raising $300 million April 29, 2026 9:01 PM - StreetInsider Avalyn Announces Pricing of Upsized Initial Public Offering April 29, 2026 9:00 PM - Globe NewsWire Form 3 Avalyn Pharma Inc. For: Apr 29 Filed by: Novo Holdings A/S April 29, 2026 8:54 PM - SEC Filing Form 3 Avalyn Pharma Inc. For: Apr 29 Filed by: FMR LLC April 29, 2026 8:44 PM - SEC Filing Form 3 Avalyn Pharma Inc. For: Apr 29 Filed by: George Simeon April 29, 2026 7:08 PM - SEC Filing Form 3 Avalyn Pharma Inc. For: Apr 29 Filed by: Carroll Jill April 29, 2026 6:53 PM - SEC Filing Form 3 Avalyn Pharma Inc. For: Apr 29 Filed by: Lavelle Erin April 29, 2026 6:48 PM - SEC Filing Form 3 Avalyn Pharma Inc. For: Apr 29 Filed by: Congleton Jon April 29, 2026 6:43 PM - SEC Filing Form 3 Avalyn Pharma Inc. For: Apr 29 Filed by: Friedman David Matthew April 29, 2026 6:39 PM - SEC Filing Form 3 Avalyn Pharma Inc. For: Apr 29 Filed by: Rhodes Melissa April 29, 2026 6:36 PM - SEC Filing Form 3 Avalyn Pharma Inc. For: Apr 29 Filed by: Turner Heather D April 29, 2026 6:32 PM - SEC Filing Form 3 Avalyn Pharma Inc. For: Apr 29 Filed by: Lazarus Howard April 29, 2026 6:27 PM - SEC Filing Form 3 Avalyn Pharma Inc. For: Apr 29 Filed by: Haviland Kate April 29, 2026 6:27 PM - SEC Filing Form 3 Avalyn Pharma Inc. For: Apr 29 Filed by: Carlson Douglas R April 29, 2026 6:25 PM - SEC Filing Form 3 Avalyn Pharma Inc. For: Apr 29 Filed by: Baranowski Lyn April 29, 2026 6:23 PM - SEC Filing Form 3 Avalyn Pharma Inc. For: Apr 29 Filed by: Golden Adam H. April 29, 2026 6:22 PM - SEC Filing Avalyn Pharma (AVLN) files for 16.67M share IPO at $16-$18/sh April 29, 2026 9:35 AM - StreetInsider Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury April 27, 2026 8:00 AM - Globe NewsWire Avalyn Pharma files for Nasdaq IPO April 8, 2026 4:04 PM - StreetInsider Avalyn Pharma adds Jon Congleton to board of directors April 6, 2026 8:00 AM - StreetInsider Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors April 6, 2026 8:00 AM - Globe NewsWire Full Article List